- cafead Aug 21, 2020 at 12:23: PM
via Yet another biotech will hit Nasdaq on Friday, and this one marks a milestone for 2020.
Cambridge, MA-based Kymera has priced its IPO, announcing a public price of $20 per share and $173.7 million raise. That’s upsized from an initial range of $16 to $18 per share, and would give the company a market value north of $900 million.
article source
Cambridge, MA-based Kymera has priced its IPO, announcing a public price of $20 per share and $173.7 million raise. That’s upsized from an initial range of $16 to $18 per share, and would give the company a market value north of $900 million.
article source